Relevant articles and documents
All total 13 Articles be found
Comparison of the full-length and 152~528 truncate of human cyclic nucleotide phosphodiesterase 4b2 for the characterization of inhibitors
Zhang, Xiang,He, Shu,Hu, Xiaolei,Wu, Jing,Li, Xinpeng,Liao, Fei,Yang, Xiaolan
, p. 49 - 58 (2019/08/06)
Aim and Objective: Human full-length cyclic nucleotide phosphodiesterase isozyme 4B2 (hPDE4B2) as the target for screening and characterizing inhibitors suffers from low activity yield and the coexistence of two conformational states bearing different aff
Synthesis, biological evaluation, and molecular modeling of new 3-(cyclopentyloxy)-4-methoxybenzaldehyde O-(2-(2,6-dimethylmorpholino)-2- oxoethyl) oxime (GEBR-7b) related phosphodiesterase 4D (PDE4D) inhibitors
Brullo, Chiara,Massa, Matteo,Rocca, Massimo,Rotolo, Chiara,Guariento, Sara,Rivera, Daniela,Ricciarelli, Roberta,Fedele, Ernesto,Fossa, Paola,Bruno, Olga
, p. 7061 - 7072 (2014/11/07)
A new series of 3-(cyclopentyloxy)-4-methoxyphenyl derivatives, structurally related to our hit GEBR-4a (1) and GEBR-7b (2), has been designed by changing length and functionality of the chain linking the catecholic moiety to the terminal cycloamine portion. Among the numerous molecules synthesized, compounds 8, 10a, and 10b showed increased potency as PDE4D enzyme inhibitors with respect to 2 and a good selectivity against PDE4A4, PDE4B2, and PDE4C2 enzymes, without both cytotoxic and genotoxic effects. The ability to enhance cAMP level in neuronal cells was assessed for compound 8. SAR considerations, also confirmed by in silico docking simulations, evidenced that both chain and amino terminal function characterized by higher hydrophilicity are required for a good and selective inhibitor-catalytic pocket interaction.
INHIBITORS OF PHOSPHODIESTERASE TYPE-IV
-
Page/Page column 14, (2008/06/13)
The present invention relates to oxazine derivatives, which can be used as selective inhibitors of phosphodiesterase (PDE) type IV. Compounds disclosed herein can be useful in the treatment of CMS disorders, AIDS, asthma, arthritis, bronchitis, chronic ob